ArticleBMC genomics2026
Impact of M and E protein mutations in SARS-CoV-2 Omicron variants on reduced antibody binding and increased structural stability: a bioinformatics study (2021-2023).
Article in BMC genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFirst identified in late 2021, the Omicron variant of SARS-CoV-2 accumulated substantially more mutations than previously circulating variants. This study investigated the genomic characteristics and structural consequences of mutations in the membrane (M) and envelope (E) proteins of dominant Omicron lineages circulating in southern Iran between March 2021 and March 2023.
methodsA total of 528 clinical samples were analyzed using next-generation sequencing (NGS), Nextclade lineage assignment, and complementary bioinformatics approaches. The structural effects of selected mutations were further evaluated using protein-protein docking, PDBe PISA interface analysis, MM/GBSA binding free energy calculations, and 100-ns molecular dynamics simulations.
resultsBetween 2021 and 2023, BA.5.2 accounted for 32.4% of sequenced isolates, whereas XBB.1.9.1 became the predominant lineage during the later phase of the study (14.2%). Structural analysis demonstrated that the interaction interface between the M protein dimer and the Fab fragment remained largely conserved across all investigated variants. However, MM/GBSA calculations revealed mutation-dependent differences in binding energetics, with the BA.5 (Q19E, A38S, A63T) variant exhibiting the least favorable binding free energy despite preservation of the overall interaction interface. Molecular dynamics simulations further showed that the investigated E protein variants maintained compact conformations with reduced conformational fluctuations relative to the wild-type protein throughout the simulation.
conclusionsCombined genomic surveillance and structural analyses demonstrated that the investigated Omicron-associated mutations largely preserved the overall architecture of the M protein-Fab interaction interface while modulating residue-level energetic contributions and the conformational dynamics of the E protein. These findings indicate that the investigated mutations primarily affect interaction energetics and protein dynamics rather than inducing major structural rearrangements. The integrated computational framework presented in this study provides a useful approach for evaluating the structural consequences of newly emerging SARS-CoV-2 variants and prioritizing mutations for future experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.